Richeldi, Luca

Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?

Wolters, P. J., Blackwell, T. S., Eickelberg, O., Loyd, J. E., Kaminski, N., Jenkins, G., Maher, T. M., Molina-Molina, M., Noble, P. W., Raghu, G., et al. (2018) · The Lancet Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseases

Cited by 196

Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria

Raghu, G., Wells, A. U., Nicholson, A. G., Richeldi, L., Flaherty, K. R., Le Maulf, F., Stowasser, S., Schlenker-Herceg, R., & Hansell, D. M. (2017) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 180

Combination therapy: the future of management for idiopathic pulmonary fibrosis?

Wuyts, W. A., Antoniou, K. M., Borensztajn, K., Costabel, U., Cottin, V., Crestani, B., Grutters, J. C., Maher, T. M., Poletti, V., Richeldi, L., et al. (2014) · The Lancet Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 150

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials

Maher, T. M., Ford, P., Brown, K. K., Costabel, U., Cottin, V., Danoff, S. K., Groenveld, I., Helmer, E., Jenkins, R. G., Milner, J., et al. (2023) · JAMA

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 148

Treatment of idiopathic pulmonary fibrosis: a network meta-analysis

Rochwerg, B., Neupane, B., Zhang, Y., Garcia, C. C., Raghu, G., Richeldi, L., Brozek, J., Beyene, J., & Schünemann, H. (2016) · BMC Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 101

Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis

Lee, J. S., Kim, E. J., Lynch, K. L., Elicker, B., Ryerson, C. J., Katsumoto, T. R., Shum, A. K., Wolters, P. J., Cerri, S., Richeldi, L., et al. (2013) · Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases

Cited by 100

Current approaches to the management of idiopathic pulmonary fibrosis

Raghu, G., & Richeldi, L. (2017) · Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseases

Cited by 90

“Velcro-type” crackles predict specific radiologic features of fibrotic interstitial lung disease

Sgalla, G., Walsh, S. L. F., Sverzellati, N., Fletcher, S., Cerri, S., Dimitrov, B., Nikolic, D., Barney, A., Pancaldi, F., Larcher, L., et al. (2018) · BMC Pulmonary Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPhonocardiography and Auscultation Techniques

Cited by 76

Pamrevlumab for the treatment of idiopathic pulmonary fibrosis

Sgalla, G., Franciosa, C., Simonetti, J., & Richeldi, L. (2020) · Expert Opinion on Investigational Drugs

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 59

No relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone

Richeldi, L., Fletcher, S., Adamali, H., Chaudhuri, N., Wiebe, S., Wind, S., Hohl, K., Baker, A., Schlenker-Herceg, R., Stowasser, S., et al. (2019) · European Respiratory Journal

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPharmacogenetics and Drug Metabolism

Cited by 34

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)

Maher, T. M., Assassi, S., Azuma, A., Cottin, V., Hoffmann-Vold, A.-M., Kreuter, M., Oldham, J. M., Richeldi, L., Valenzuela, C., Wijsenbeek, M. S., et al. (2023) · BMJ Open Respiratory Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 28

Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments

De Biasi, S., Cerri, S., Bianchini, E., Gibellini, L., Persiani, E., Montanari, G., Luppi, F., Carbonelli, C. M., Zucchi, L., Bocchino, M., et al. (2015) · BMC Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 28

Quantitative analysis of lung sounds for monitoring idiopathic pulmonary fibrosis: a prospective pilot study

Sgalla, G., Larici, A. R., Sverzellati, N., Bartholmai, B., Walsh, S. L. F., Nikolic, D., Barney, A., Fletcher, S., Jones, M., Davies, D. D., et al. (2019) · European Respiratory Journal

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPhonocardiography and Auscultation Techniques

Cited by 15